🩺 Cannot agree more with the concerns Heads of Medicines Agencies #HMA sent to @EU_Health re #MedicalDevices regulation!
📉 We cannot rush and repeat the mistakes, we need an impact assessment before any potential revision!
🙏🏻 Let's be reasonable and drop the #100Days!
The #DraghiReport failed to address societal benefit and sustainable growth. It is a short-sighted neo-liberal manifesto. In health it solely focuses on #pharma competitiveness and completely forgets why we make drugs in the first place, to make sure #patients get treated 🙄
"I think no one was better placed than you, dear Mario, to carry out a thorough analysis of Europe's competitiveness – and how to improve it.
Now there is wide consensus that it must be at the top of our agenda, and at the heart of our action."
— President @vonderleyen
✅️ A day after @Europarl_EN approved trilogue agreement on the #SoHO regulation, I saw this soon to be banned advert on the Prague metro.
🩸Clearly, it's all about #VUD and solidarity....
🇪🇺 Hope new rules will be implemented properly and we achieve more altruism in donations!
@carlomartu Loving this fake news from big pharma, as if it mattered where the R&D and production is made when giving out RDP🙄 Also careful about not mixing RDP with market protection that follows, RDP now is 8 full stop.
@AIM_Healthcare@EP_Environment I think it would be helpful not to call it all RDP as I am assuming you are confusing data and market protection here...today it is 8 years RDP + up to 3 years market protection = 11...
We extend our gratitude to our Session 2 speakers @AnnaProEU, Javier de la Cueva, Anne Hendrickx and Suzannah Chapman for their impactful contributions to the discussion.
@OECD@civio@beuc@AnnaProEU: "The @EU_Commission's proposal in the pharma directive on reporting on public R&D funding is a good step. But to achieve fairer prices, we need clear info on total R&D costs & the percentage of financing coming from govts, non-profit research, as well as tax breaks."
3 days to go till our 6th #AccesstoMedicines Forum!
Explore crucial topics like pharmaceutical legislation, antibiotic development & fair pricing & listen to insights from our ten distinguished speakers.
📆8 Dec
🕤9:30-13:00 CET
Have you registered yet?🔗https://t.co/Wtne8U8CGY
We're deeply saddened by the death of our colleague Michèle Rivasi.
Her remarkable career, passionate political battles & empathy have left their mark on all those who had the chance to meet her.
Our thoughts are with her family & friends.
Our statement:https://t.co/soVbNUxk9o
🔴 Sensational! EU Parliament brushes Sustainable Use of Plant Protection Products Regulation off the table. This means no bans on #plantprotectionproducts in bird sanctuaries for the time being. Farmers can be relieved for now. #SUR@EPPGroup
🤔Really wondering why lobbyists are not able to make this very simple calculation, so here it is:
1 week before amendments deadline / 420 articles + recitals + annexes = nope, I will not meet and discuss proposals you sent me today 🤦♀️
#pharma
The STOA study “Improving access to medicines & promoting pharmaceutical innovation" was prematurely & erroneously published on Friday 27/10 before finalisation and before adding methodological clarifications - see also thread below
@mepassistants Sure, but ideally there is some critical thinking process and adjustment before submission, which unfortunately not always happens and what we have is brainless copy paste :/ In any case quite good politico covers this stuff
1) @EP_ScienceTech develops a study on #IP incentives and other tools to incentivise R&D
2) Industry and EPP are not really thrilled about what the study concludes
3) Suddently the study is taken off the website and is being pulled, in a green week so it goes unnoticed...
🤮🤮
Excellent study presented today on #RDincentives & #access2medicines!
Clear that data and IP protection is not the right tool to steer R&D in unmet needs. Absurd that @EU_Health used it as its sole chip in the pharma package! Clearly only works for me-too meds...🤦♀️
One must wonder why this comes only after S&D traded voting in favour of Hoekstra to get Sefcovic as Commission EVP, but applauding this nevertheless!!
We welcome today's decision by @PES_PSE to suspend Slovak SMER and HLAS parties memberships.
The S&D Bureau will propose to the Group to suspend its 3 Slovak MEPs at next week's group meeting.
Full statement⬇️
https://t.co/zXlkSGQ5hS